Genetic Testing in Lung Cancer

Identification of actionable mutations, deletions and driver gene fusions in NSCLC and SCLC can help guide targeted treatment regimens

9+1
Target Genes

1. EGFR
2. BRAF
3. MET
4. ERBB2
5. KRAS
6. ALK
7. RET
8. ROS
9. NTRK + PDL-1

Highlights of Genetic Testing Panel

Liquid Biopsy - Cell free DNA for EGFR available
TAT for complete Oncomine Panel 2 weeks only
Tests available individually also
Fresh tissue / FFPE block accepted

Includes Mutations, Deletions, Fusion genes and PDL-1 overexpression commonly reported in NSCLC and SCLC
EFGR - by Liquid Biopsy

Individual Testing Solutions for Lung Cancer

EGFR Mutation Testing*

To detect mutations in the EGFR gene for the detection of 42 mutations
(exons 18, 19, 20, and 21)

Sample type – FFPE tissue block
Method – Real time – PCR
TAT – 5 days

Liquid Biopsy Available

KRAS Mutation Testing

To detect mutations in the KRAS oncogene for detection of 7 mutations in codon 12 and 13

Sample type – FFPE tissue block
Method – Real time – PCR
TAT – 5 days

BRAF Mutation Testing

To detect hotspot mutation in V600E codon of exon 15 in the BRAF gene

Sample type – FFPE tissue block
Method – Real time – PCR
TAT – 7 days

ROS-1 by FISH

To detect the ROS1 gene rearrangement

Sample type – FFPE tissue block
Method – Fluorescence In Situ Hybridization
TAT – 7 days

ALK by IHC

To detect for ALK gene rearrangement

Sample type – FFPE tissue block
Method – Immunohistochemistry (IHC)
TAT – 4 days

PDL - 1 Testing

To detect over expression of PDL-1 by tumor and Immune cells SP-142 Clone Ventana

Sample type – FFPE tissue block
Method – Immunohistochemistry (IHC)
TAT – 4 days

References -

https://www.jmdjournal.org/article/S1525-1578(17)30590-1/fulltext

Central Processing Center

Anderson Diagnostics and Labs,
No.26, Rajarathinam Street,
Kilpauk, Chennai - 600010.

Get Directions

HELP LINE

+917305988862

Oncomine Focus Assay Panel for Lung Cancer with PDL-1 Testing

Hot spot screening of relevant, druggable mutations, copy number changes and fusions for various Cancers
ACMG/AMP guidelines-based reporting with drugs and target information
NGS based assay eliminates need of multiple technology FISH, IHC, Realtime
Complete screening of relevant gene in single sample

Sample Type
FFPE Block or Fresh Tissue in ONCO-Bank
TAT - 2 to 3 weeks

Gene	Molecular aberration	Prevalence in NSCLC	Prevalence in SCC
EGFR	Mutations (exons 18 – 21)	28%	9%
BRAF	Mutations	5%	4%
MET	Mutations	10%	4%
RET	Fusions or rearrangements	4%	4%
ERBB2	To detect mutations	7%	5%
KRAS	To detect mutations	23%	5%
ALK	Fusions or rearrangements	7%	5%
ROS	Fusions or rearrangements	4%	8%
NTRK	Fusions or rearrangements	3%	6%

(Adapted from cbioportal.org)

List of FDA Approved Targeted Drugs Covered

Biomarker
Drugs
Disease



BRAF V600E; BRAF V600K
Vemurafenib, Cobimetinib, Dabrafenib, Trametinib, Atezolizumab, Encorafenib
Melanoma, NSCLC, CRC

ALK Fusion, EML4-ALK
Crizotinib, Ceritinib, Alectinib, Brigatinib, Lorlatinib
NSCLC

EGFR
Cetuximab, Mobocertinib, Afatinib, Gefitinib, Amivantamb, Osimertinib, Erlotinib
Lung cancer

ERBB2
Fam-trastuzumab Deruxtecan-nxki
NSCLC

KRAS
Cetuximab, Panitumumab, Sotorasib
CRC, NSCLC

MET, exon skipping
Capmatinib
NSCLC

RET-Fusions
Pralsetinib, Selpercatinib
NSCLC

Ros1-fusions
Entrectinib, Crizotinib
NSCLC

Biomarker	Drugs	Disease
BRAF V600E; BRAF V600K	Vemurafenib, Cobimetinib, Dabrafenib, Trametinib, Atezolizumab, Encorafenib	Melanoma, NSCLC, CRC
ALK Fusion, EML4-ALK	Crizotinib, Ceritinib, Alectinib, Brigatinib, Lorlatinib	NSCLC
EGFR	Cetuximab, Mobocertinib, Afatinib, Gefitinib, Amivantamb, Osimertinib, Erlotinib	Lung cancer
ERBB2	Fam-trastuzumab Deruxtecan-nxki	NSCLC
KRAS	Cetuximab, Panitumumab, Sotorasib	CRC, NSCLC
MET, exon skipping	Capmatinib	NSCLC
RET-Fusions	Pralsetinib, Selpercatinib	NSCLC
Ros1-fusions	Entrectinib, Crizotinib	NSCLC